zilovertamab
merck
['zilovertamab', 'lymsm', 'cll']
congress #asco22 | q&amp;a: hun ju lee, md asked about biological factors that may be contributing to the differential effect zilovertamab had in #cll vs #mcl a: it appears to be the complementary nature of inhibiting the bcr and ror1 pathways together. #lymsm
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm